期刊文献+

正交分析法优选半乳糖化羧甲基壳聚糖磁性纳米载体的制备条件

Optimize the preparing condition of galactosylated-carboxymethyl chitosan-magnetic iron oxide nanoparticles by orthogonal method
下载PDF
导出
摘要 目的:优选半乳糖化羧甲基壳聚糖磁性纳米载体(galactosylated-carboxymethyl chitosan-magnetic iron ox-ide nanoparticles,Gal-CMCS-Fe3O4NP)的制备条件。方法 :采用正交分析试验方法 ,以Fe3O4NP与羧甲基壳聚糖(car-boxymethyl chitosan,CMCS)质量比、pH值和搅拌时间为考察因素,纳米载体的粒径和磁响应性为考察指标。结果 :Fe3O4NP与CMCS的质量比为1∶2、pH值为7、搅拌时间为1 h时为最佳制备条件,最终所制备的Gal-CMCS-Fe3O4NP的平均粒径为20 nm,具有较好的磁响应性。结论:获得较满意的Gal-CMCS-Fe3O4NP的制备条件,纳米载体性状符合要求。 Objective: To optimize the preparing condition of galactosylated-carboxymethyl chitosan-magnetic iron oxide nanoparticles(Gal-CMCS-Fe3O4NP).Methods: Orthogonal experiment was designed with the particle diameter and magnetic property as index,and with quality ratio between Fe3O4NP and carboxymethyl chitosan(CMCS),pH and the stirring time as factors.Results: The orthogonal analysis indicated that the optimal preparation conditions was followed,quality ratio between Fe3O4NP and carboxymethyl chitosan(CMCS) was 1∶2,pH was 7 and the stirring time was 1 hour.The final Gal-CMCS-Fe3O4NP have good magnetic property,and the average particle diameter is 20 nm.Conclusion: With this method,a satisfactory preparing condition can be obtained,and the character of the nanoparticles is desirable.
出处 《南通大学学报(医学版)》 2012年第5期350-352,共3页 Journal of Nantong University(Medical sciences)
基金 国家自然科学基金青年基金资助项目(81000984) 江苏省高校自然科学研究面上资助项目(10KJB320014) 南通市社会发展科技计划资助项目(S2010019) 江苏省"六大人才高峰"资助项目(2011-WS066)
关键词 正交试验 磁性纳米粒子 羧甲基壳聚糖 半乳糖 orthogonal test magnetic nanoparticles carboxymethyl chitosan galactose
  • 相关文献

参考文献6

  • 1Leng F, Wan J, Liu W, et a]. Prolongation of epidural anal- gesia using solid lipid nanoparticles as drug carrier for li- docaine[J]. Reg Anesth Pain Med, 2012, 37(2):159-165.
  • 2Maeda H. The enhanced permeability and retention(EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting[J]. Adv Enzyme Regul, 2001, 41 : 189-207.
  • 3Allen TM. Ligand-targeted therapeutics in anticancer ther- apy[J]. Nat Rev Cancer, 2002, 2(10):750-763.
  • 4Thurmond KB 2nd, Remsen EE, Kowalewski T, et al. Packaging of DNA by shell erosslinked nanoparticles [J]. Nucleic Acids Res, 1999, 27(14):2966-2971.
  • 5王国斌,夏泽锋,陶凯雄,周立国,刘敬伟,肖勇,李剑星.医用纳米级Fe_3O_4磁流体的急性毒理学实验研究[J].华中科技大学学报(医学版),2004,33(4):452-454. 被引量:14
  • 6黄伟,崔光华,贺俊峰,周旭,张强.壳聚糖纳米粒用作基因递送载体的初步研究[J].药学学报,2002,37(12):981-985. 被引量:28

二级参考文献23

  • 1Lubbe A S, Bergemann C, Riess H et al. Clinical experiences with magnetic drug targeting: a phase Ⅰ study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res, 1996, 56:4686
  • 2Susan E M, Colin W P, Michael D T. Macromolecular systems for chemotherapy and magnetic resonance imaging. Adv Drug Deliv Rev, 1996, 18:219
  • 3Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug DelivRev, 2003, 55:329
  • 4Goodwin S C, Bittner C A, Peterson C L et al. Singledose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol Sci, 2001, 60:177
  • 5Jordan A, Scholz R, Wust P et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinomainvivo. Int J Hyperthermia, 1997, 13:587
  • 6Guidance for industry. single dose acute toxicity testing for pharmaceuticals. CEDR, 1996. 1~2
  • 7Toxicokinetics: the assessment of systemic exposure in toxicity studies. CEDR, 1995. 9~10
  • 8WHO food additives series 6: toxicological evaluation of some food colours, enzymes, flavours enhancers, thickening agents and certain food additives. WHO, 1974.
  • 9Hafeli U O, Gayle J P. In vitro and in vivo toxicity of magnetic microspheres. JMMM, 1999, 194:76
  • 10Wagner S, Schnorr J, Pilgrimm H et al. Monomer coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol, 2002,37: 167

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部